The burden of arthritis and nonsteroidal anti-inflammatory treatment: A european literature review

PharmacoEconomics

Volumn 19, Issue , 2001, Pages 1-15

  Hunsche, Elke ^a,c   Chancellor, Jeremy V M ^a   Bruce, Nick ^b  

^a Pharmacia Corporation   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTHROTEC; DICLOFENAC; ETODOLAC; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; SULINDAC;

ADOLESCENT; ADULT; AGED; CAREGIVER; CHILD; COST BENEFIT ANALYSIS; DISABILITY; EUROPE; FEMALE; GASTROINTESTINAL TOXICITY; HEALTH CARE COST; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; RESOURCE ALLOCATION; REVIEW; RHEUMATOID ARTHRITIS;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CHILD; COST OF ILLNESS; DIRECT SERVICE COSTS; ECONOMICS, PHARMACEUTICAL; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS;

EID: 0035131391     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200119001-00001     Document Type: Review

References (45)

1. The epidemiology of osteoarthritis
2. Assessment of long-term outcomes of rheumatoid arthritis: How choices of measures and study designs may lead to apparently different conclusions
3. The prevalence and impact of arthritis in older persons
4. The cost of rheumatoid arthritis
5. Prevalence of rheumatoid arthritis
6. Direct cost of rheumatoid arthritis during the first six years: A cost-of-illness study
7. A panorama of rheumatic diseases Das Panorama des rheumatischen Formenkreises
8. Economics of arthritis: A global perspective
9. Health economics in rheumatology
10. A pilot study of the economic cost and clinical outcome of day patient vs inpatient management of active rheumatoid arthritis
11. Disablement associated with rheumatic disorders in a British population: Problems with activities of daily living and level of support
12. Impact of disablement due to rheumatic disorders in British population: Estimates of severity and prevalence from the Calderdale Rheumatic disablement survey
13. Demographic and epidemiological determinants of healthcare costs in The Netherlands: Cost of illness study
14. Locomotion status and costs in destructive rheumatoid arthritis: A comprehensive study of 82 patients from a population of 13,000
15. The costs of rheumatoid arthritis
16. Treatment of rheumatoid arthritis - Does it affect society's cost for the disease?
17. Patient-centered evaluation of illness outcome in musculoskeletal diseases: Adaptation and revision of outcome instruments
18. Early rheumatoid arthritis - Some social, economical, and psychological aspects
19. Musculoskeletal disorders as determinants of disability in Finns aged 30 years or more
20. Socioeconomic evaluation of rheumatoid arthritis and osteoarthritis: A literature review
21. Socioeconomic costs of osteoarthritis in France
22. Review article: Controversies in NSAID-induced gastroduodenal damage - Do they matter?
23. Pharmacoeconomics of nonsteroidal anti-inflammatory drugs
24. Misoprostol: Pharmacoeconomics of its use as prophylaxis against gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs
25. The economic consequences of NSAID-induced gastrointestinal damage
26. Epidemiology and economics of NSAID-induced gastropathy
27. Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs
28. The economic consequences of NSAID-induced gastropathy in the United Kingdom and commentary on the article by G. De Pouvourville
29. Cost-effectiveness of misoprostol in Sweden
30. Preventing NSAID induced gastrointestinal toxicity - Economic considerations, methodological problems and results
31. The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis
32. Evaluating the real cost of NSAID therapy: "Shadow costs" relating to the treatment of gastrointestinal side effects
33. The economic consequences of NSAID-induced gastropathy: The French context
34. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAIDs in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions
35. Gastrointestinal events in patients prescribed non-steroidal anti-inflammatory drugs: A controlled study using record linkage in Tayside
36. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use
37. Cost of NSAID adverse effects to the UK National Health Service
38. Prescribing of nonsteroidal anti-inflammatory drugs in general practice: Determinants and consequences
39. The treatment of arthritis: A survey of current medical and patient opinion
40. Economic costs of functional dyspepsia
41. The distribution of health care costs and their statistical analysis for economic evaluation